Kepler Capital Markets reiterated their buy rating on shares of AstraZeneca plc (LON:AZN) in a report issued on Monday morning. The brokerage currently has a GBX 5,200 ($67.16) price objective on the biopharmaceutical company’s stock.

Several other research firms have also recently issued reports on AZN. Morgan Stanley restated an overweight rating and set a GBX 5,600 ($72.32) price objective on shares of AstraZeneca plc in a report on Friday, June 23rd. UBS AG set a GBX 5,150 ($66.51) target price on AstraZeneca plc and gave the company a neutral rating in a report on Tuesday, June 27th. Shore Capital reiterated a hold rating on shares of AstraZeneca plc in a report on Wednesday, June 21st. Barclays PLC reiterated an overweight rating and issued a GBX 6,000 ($77.49) target price on shares of AstraZeneca plc in a report on Monday, June 5th. Finally, J P Morgan Chase & Co reiterated a neutral rating on shares of AstraZeneca plc in a report on Monday, June 5th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and nine have given a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus price target of GBX 5,022.91 ($64.87).

AstraZeneca plc (LON AZN) opened at 4806.00 on Monday. The stock has a 50 day moving average price of GBX 4,566.78 and a 200 day moving average price of GBX 4,881.73. The firm’s market cap is GBX 60.84 billion. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00.

TRADEMARK VIOLATION WARNING: This report was first posted by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.dailypolitical.com/2017/09/14/astrazeneca-plcs-azn-buy-rating-reaffirmed-at-kepler-capital-markets.html.

The company also recently disclosed a dividend, which was paid on Monday, September 11th. Investors of record on Thursday, August 10th were issued a GBX 68.90 ($0.89) dividend. This represents a yield of 1.35%. The ex-dividend date of this dividend was Thursday, August 10th.

In other news, insider Nazneen Rahman acquired 39 shares of the stock in a transaction that occurred on Thursday, July 27th. The stock was purchased at an average cost of GBX 4,370 ($56.44) per share, with a total value of £1,704.30 ($2,201.08).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.